Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation

Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation

The choice of drugs for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis (SS) is currently very limited. Data from a number of studies show that rituximab (RTM) can improve lung function and reduce the severity of skin fibrosis in patients with SS.Objective: to eva...

Full description

Bibliographic Details
Main Authors:	L. P. Ananyeva, O. A. Koneva, O. V. Desinova, L. A. Garzanova, S. I. Glukhova, M. N. Starovoitova, O. B. Ovsyannikova, A. V. Volkov, A. P. Aleksankin, E. L. Nasonov
Format:	Article
Language:	Russian
Published:	IMA-PRESS LLC 2019-07-01
Series:	Научно-практическая ревматология
Subjects:	systemic sclerosis interstitial lung disease anti-b cell therapy rituximab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2724

Similar Items

Effect of rituximab on heart involvement in systemic sclerosis
by: L. A. Garzanova, et al.
Published: (2019-01-01)

Short-term absolute B-cell counts monitoring in systemic sclerosis patients treated with rituximab
by: L. P. Ananieva, et al.
Published: (2020-09-01)

THE IMPORTANCE OF HIGH-RESOLUTION COMPUTED TOMOGRAPHY IN EVALUATING THE EFFICACY OF RITUXIMAB IN PATIENTS WITH INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS
by: O. A. Koneva, et al.
Published: (2018-11-01)

CHANGES OF ACTIVITY INDEX AND TOTAL SEVERITY INDEX IN PATIENTS WITH SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE OVER A 5-YEAR FOLLOW-UP PERIOD
by: O. B. Ovsyannikova, et al.
Published: (2016-07-01)

Rituximab treatment in patients with systemic sclerosis and interstitial lung disease
by: Abdel Gaffar A Mohammed, et al.
Published: (2017-01-01)

RITUXIMAB TREATMENT FOR INTERSTITIAL LUNG INJURY IN SCLERODERMA SYSTEMATICA
by: Lidia Petrovna Ananieva, et al.
Published: (2013-12-01)

Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis
by: Marina Maria Vieira de Figueiredo Caldas, et al.
Published: (2021-02-01)

Clinical and laboratory characteristics of patients with systemic sclerosis positive for anti-ribonucleoprotein antibodies
by: R. U. Shayakhmetova, et al.
Published: (2019-11-01)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

Interstitial lung disease in systemic sclerosis (systemic scleroderma)
by: L. P. Ananyeva, et al.
Published: (2021-03-01)

Comparative characteristics of the main phenotypes of systemic sclerosis
by: R. U. Shayakhmetova, et al.
Published: (2020-02-01)

Effects of treatment with rituximab on microcirculation in patients with long-term systemic sclerosis
by: Verônica Silva Vilela, et al.
Published: (2018-12-01)

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 2. Safety and complications
by: O. B. Ovsyannikova, et al.
Published: (2021-02-01)

Autologous hematopoietic stem cell transplantation in the treatment of systemic sclerosis. Part 1. Clinical aspects
by: O. B. Ovsyannikova, et al.
Published: (2020-11-01)

Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
by: Qasim Akram, et al.
Published: (2016-03-01)

CLINICAL EVALUATION OF THE MANIFESTATIONS OF INTERSTITIAL LUNG INJURYIN SYSTEMIC SCLERODERMA FROM HIGH-RESOLUTION COMPUTER T OMOGRAPHY DATA
by: L P Anan'eva, et al.
Published: (2011-04-01)

Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis
by: Carolin Schwake, et al.
Published: (2020-10-01)

Profile of autoantibodies in systemic sclerosis
by: M. N. Starovoitova, et al.
Published: (2016-10-01)

OPPORTUNITIES OF ANTI B-CELL THERAPY IN MULTIPLE SCLEROSIS
by: E. P. Evdoshenko, et al.
Published: (2014-07-01)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
by: Serena Brancati, et al.
Published: (2021-07-01)

ASSESSMENT OF THE SENSITIVITY OF NEW CRITERIA FOR SYSTEMIC SCLEROSIS IN RUSSIAN PATIENT POPULATION
by: O. A. Koneva, et al.
Published: (2015-09-01)

Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center
by: Verônica Silva Vilela, et al.

Successful treatment of interstitial pneumonia with autoimmune features using rituximab as salvage therapy
by: Abeline Kapuczinski, et al.
Published: (2021-05-01)

Oxygen-Dependent Patient with Antisynthetase Syndrome Associated Interstitial Lung Disease Responds Promptly to Rituximab with Rapid Pulmonary Function Improvement
by: Robert Chao, et al.
Published: (2017-01-01)

Good response to rituximab in a patient with granulomatosis with polyangiitis and pulmonary, renal manifestations and ophthalmoplegia.
by: Carolina Díez-Morrondo, et al.
Published: (2016-01-01)

USE OF RITUXIMAB IN PATIENTS WITH SYSTEMIC MANIFESTATIONS OF PRIMARY SJOGREN'S SYNDROME
by: O. A. Logvinenko, et al.
Published: (2014-12-01)

Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis
by: Mattia Pozzato, et al.
Published: (2021-01-01)

A case of sine scleroderma with parenchymal lung disease
by: Mansoor Karimifar, et al.
Published: (2014-01-01)

Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis
by: Paul Gressenberger, et al.
Published: (2021-06-01)

Assessment of lung ultrasound in patients with scleroderma systematica and interstitial lung disease
by: Olga Borisovna Ovsyannikova, et al.
Published: (2013-06-01)

Intersticial pulmonary disease in patients with systemic sclerosis. Narrative review of the literature
by: Álvarez-Barreneche, María Fernanda, et al.
Published: (2017-07-01)

Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review
by: Belén Atienza-Mateo, et al.
Published: (2020-09-01)

Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: Preliminary data
by: O A Logvinenko, et al.
Published: (2012-12-01)

Rituximab Utilization Evaluation with Focused on Available Evidence for Off-Labeled Indications
by: Sohrab Aghabeigi, et al.
Published: (2019-08-01)

Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure
by: Zappa Maria, et al.
Published: (2011-08-01)

Rituximab induced cytokine release syndrome in an MS patient: A case report
by: Masoud Etemadifar, et al.
Published: (2021-07-01)

USE OF RITUXIMAB IN PATIENTS WITH LUPUS NEPHRITIS
by: Anna Vasilyevna Torgashina, et al.
Published: (2010-08-01)

Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease
by: Bergamasco A, et al.
Published: (2019-04-01)

Rituximab-induced interstitial lung disease in a patient with follicular lymphoma: A rare case report
by: Suhas Aagre, et al.
Published: (2015-01-01)

STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
by: O A Koneva, et al.
Published: (2011-08-01)

Cannot write session to /tmp/vufind_sessions/sess_jdrd33q2u0jp3dn69rl6mjmeb8